Toronto, Ontario – December 24, 2025 - PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to have publicly filed its financial results for the periods ended August 31, 2025 and November 30th, respectively. All figures are reported in Canadian dollars. The Company’s full set of Audited Financial Statements for the 2025 fiscal year, as well as its unaudited condensed interim consolidated financial statements for the first quarter of its 2026 fiscal year, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at www.PharmAla.ca and its profile page on SEDAR+ at www.sedarplus.ca.
“Commencing in late 2025 and continuing into Q1 2026 we have taken major steps towards the development of our novel molecules and look to continue this momentum throughout the remainder of fiscal 2026 with the goal of commencing our Phase 2a/b clinical trial in Australia,” said Nick Kadysh, CEO, PharmAla Biotech. “While we have been prioritizing our development, we have continued to see great traction in demand for our LaNeo™ MDMA, which has continued to grow our pipeline of clinical trial sales. With the approval of reimbursement for medical treatments using LaNeo MDMA in Australia, both by private medical insurers and by the Australian Department of Veterans Affairs (“DVA”), we believe that this trend will only continue.”
Financial Highlights:
Customer deposits have continued to grow consistently:
“We have filed our short-form prospectus, secured a lending partner in Australia and have grown our clinical trial revenue pipeline and related customer deposits, all of which will help us to fund our clinical trial and development work,” said Will Avery, CFO, PharmAla Biotech. “With these pieces in play we are excited for the growth we anticipate for PharmAla in the year ahead.”
PharmAla Biotech Holdings Inc. (CSE: MDMA) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials, and to develop novel drugs in the same class. PharmAla is a “regulatory first” organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators. Our team of dedicated professionals includes regulatory experts, scientists, and biomanufacturing professionals. PharmAla has built what it believes to be North America’s first cGMP MDMA value chain, encompassing GMP manufacturing of Active Pharmaceutical Ingredient (API), and drug product formulation. PharmAla’s research and development unit has also begun preclinical research into two patented Novel Chemical Entities (NCEs) based on MDXX class molecules, with proof-of-concept research currently ongoing at the University of Arkansas Medical School.
Nicholas Kadysh, CEO
press@pharmala.ca